April 15, 2010—California Peptide Research, Inc. (CPRI) announced today it has been awarded a blanket purchase agreement (BPA) by the National Institutes of Health (NIH) for its peptide products and consulting services. The BPA is effective April 15, 2010 and has no purchase limit for the NIH research community. According to the terms of the BPA, NIH researchers can access a complete catalog of custom and catalog peptides and services needed to facilitate experimental research and improve outcomes. “California Peptide Research, Inc.
News
California Peptide Research, Inc. introduces HFIP treated beta amyloids
April 1, 2010 — California Peptide Research, Inc. (CPRI) announces the introduction of HFIP (hexafluoroisopropanol) treated beta amyloids to its existing catalog of neuropeptides. The new HFIP treated beta amyloids will be offered in the 1-40 and 1-42 variants in 1.0 mg and 0.5 mg quantities.